Filter results by document type and/or working area to find what you're searching for.
The clinical information card describes the clinical challenges during haematopoietic stem cell transplantation (HSCT) treatment. The case of an oncologic patient is described and the benefits of our analysers for monitoring of infections, thrombocytopenia and engraftment are emphasised.
The detection of blast cells in the peripheral blood is considered extremely important, and great responsibility is placed on the investigating laboratory. As well as informa¬tion on the physiology, this SEED article describes the possible causes of the release of blast cells into the blood, the char¬acteristics by which they can be identified and how further diagnosis is carried out.
With this clinical case report an example of a rare blastic plasmacytoid dendritic neoplasm (BPDCN) as it occurred on the XN-Series analyser is described. The measurements were carried out directly after treatment and three months later. The distribution of WBC in the WDF scattergrams were abnormal and the XN analyser indicated these abnormalities with the flags ‘Blasts?’ and ‘Abn Lympho?’ and the subsequent manual smear review revealed the presence of blasts.
This SEED article is meant to explain the findings focused on cell count and differentiation for pleural, ascitic, cerebrospinal and synovial fluid as well as for CAPD. Traditionally, body fluid counts are performed by manual counting under a microscope using a haemocytometer, but laboratories now have the option of automating their manual processes using automated haematology or urinalysis analysers. This SEED summarises the advantages and disadvantages of haemocytometry and Sysmex analysers and explains briefly the XN-BF mode.
For over 450 000 women each year across Europe, a diagnosis of breast cancer is the start of a difficult and stressful journey. Healthcare professionals work diligently to provide the best possible treatment and outcome for all patients.
Follicular lymphoma (FL) is the most common form of indolent lymphoma in the western world, accounting for approximately 25% of malignant lymphomas (Ciabanu et al 2013). Disease progression of FL is often unpredictable with 25% - 30% of FL cases progressing; most commonly to diffuse large B cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma and rarely B-lymphoblastic leukaemia/lymphoma (B-ALL) (Swerdlowetal, 2017).